Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
This article was originally published in The Pink Sheet Daily
Executive Summary
In an age of diabetes drug safety scares, will patients turn off of the thiazolidinedeione class altogether, or will the warning go unnoticed?
You may also be interested in...
Charting The Course Of Product Liability: From Yasmin/Yaz To Actos
Bayer’s birth control pills Yasmin and Yaz face the most pharmaceutical product liability actions in federal court followed by Pfizer’s Prempro and GlaxoSmithKline’s Avandia. While GSK has settled the bulk of cases before a single trial, Merck and Novartis are winning Fosamax and Aredia jury verdicts.
Takeda Re-Files DPP-4 Inhibitor Alogliptin, Plays Up Combo With Actos
As a means of differentiating its just-resubmitted diabetes drug alogliptin, Takeda Pharmaceutical Company Ltd. is playing up a fixed-dose combination with its blockbuster Actos, even though the latter drug has been hit hard by a potential link to bladder cancer.
Takeda Re-Files DPP-4 Inhibitor Alogliptin, Plays Up Combo With Actos
As a means of differentiating its just-resubmitted diabetes drug alogliptin, Takeda Pharmaceutical Company Ltd. is playing up a fixed-dose combination with its blockbuster Actos, even though the latter drug has been hit hard by a potential link to bladder cancer.